Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSC-04 in COVID-19 respiratory distress
NCT04486001Phase 1Completed
- Sponsor
- Sorrento Therapeutics
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of COVI-MSC in coronavirus disease 2019 (COVID-19), sponsored by Sorrento Therapeutics. Primary endpoints: Frequency of all adverse events at 3 months, Frequency of infusion related serious adverse events and 1 more. Started Dec 2020; status: completed.
02
Drugs
COVI-MSC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04486001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486001.